As of May 29, 2025, Kindred Biosciences Inc (KIN) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Kindred Biosciences Inc's Forward P/E to Peers
To better understand Kindred Biosciences Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Kindred Biosciences Inc (KIN) | - |
| Vertex Pharmaceuticals Inc (VRTX) | 23.87 |
| Regeneron Pharmaceuticals Inc (REGN) | 16.17 |
| Abbvie Inc (ABBV) | 14.52 |
| Gilead Sciences Inc (GILD) | 13.36 |
| Amgen Inc (AMGN) | 12.92 |
Compared to its competitors, Kindred Biosciences Inc's Forward P/E is difficult to compare due to insufficient data.